{"entity":{"id":"paper-intuitt-nf2-brigatinib-plotkin-nejm-2024","kind":"paper","name":"INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours","aka":[],"tldr":"In people with the inherited condition NF2 whose nerve and brain-lining tumours were growing despite earlier treatment, the kinase inhibitor brigatinib shrank some tumours, slowed the growth of all types and improved hearing in a third of affected ears without serious toxicity.","summary":"First sub-study of the adaptive platform trial INTUITT-NF2: 40 patients (median age 26) with NF2-related schwannomatosis and progressive target tumours (10 vestibular schwannomas, 8 non-vestibular schwannomas, 20 meningiomas, 2 ependymomas) received brigatinib.\n\nAfter a median follow-up of 10.4 months, 10 percent of target tumours and 23 percent of all tumours had a radiographic response, with meningiomas and non-vestibular schwannomas benefiting most; annualised growth rates fell for all tumour types; hearing improved in 35 percent of eligible ears; pain scores fell; and there were no grade 4 or 5 treatment-related adverse events.","asOf":"2026-09-22","links":[{"label":"N Engl J Med 2024","url":"https://doi.org/10.1056/NEJMoa2400985"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38904277/"}],"tags":[],"related":[],"cancers":["vestibular-schwannoma","meningioma"],"sections":[],"technologies":[],"targets":[],"drugs":["brigatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["intuitt-nf2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/NEJMoa2400985","pmid":"38904277","authors":"Plotkin SR, Yohay KH, Nghiemphu PL, et al.","paperType":"observational","findings":["Radiographic response in 10 percent (95% CI 3 to 24) of target tumours and 23 percent (16 to 30) of all tumours.","Annualised growth rates decreased for every tumour type during treatment.","Hearing improvement in 35 percent (95% CI 20 to 53) of eligible ears; no grade 4 or 5 treatment-related adverse events."],"whatItMeans":"Brigatinib is the first drug shown to act across the tumour types of NF2-related schwannomatosis and is now offered for progressive tumours; the platform design lets further drugs be tested against the same benchmark.","caveats":["Single-arm sub-study with short follow-up; responses were modest by size criteria.","Vestibular schwannomas responded less than meningiomas and non-vestibular schwannomas."],"changedPractice":true,"participants":40},"route":"/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/","neighbours":{"cancer":[{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/"}],"drug":[{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/"}],"trial":[{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}